linjc16/ctgov huggingface dataset:
Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia

Study Overview
=================
Brief Summary
-----------------
The purpose of the questionnaire is to find risk factors for the development of post-traumatic stress disease (PTSD) in health workers during COVID-19 pandemy.

Official Title
-----------------
PTSD in Health Workers During COVID-19 Pandemia

Conditions
-----------------
COVID, Post Traumatic Stress Disorder

Intervention / Treatment
-----------------
* Behavioral: Maslach Burnout Inventory (MBI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: workers in health services, including phisicians, nurses, inhospital technicians and biologists

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Health workers<br>They include doctors, nurses, techinicians, biologists and other non technical inhospital workers | Behavioral: Maslach Burnout Inventory (MBI)<br>* The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with diagnosis of PTSD. | PTSD consists in job burnout, including emotional exhaustion, depersonalization, and personal accomplishment. | Through study completion, an average of 1 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.

Official Title
-----------------
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: ITCA 650 60 mcg/day
* Drug: glimepiride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HbA1c between 7.5% - 10.5% on metformin monotherapy BMI between 25 & 45 kg/m2 Exclusion Criteria: on thiazolidinedione, sulfonylureas, DPP-4, exenatide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months history of pancreatitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ITCA 650 60 mcg/day<br>ITCA 650 is exenatide in DUROS | Drug: ITCA 650 60 mcg/day<br>* exenatide in DUROS<br>|
| Active Comparator: glimepiride<br>glimepiride up-titrated to 8 mg/day over first 13 weeks | Drug: glimepiride<br>* oral glimepiride does-escalated,if tolerated, to 8 mg/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c | 52-Week Treatment Period | 52 weeks |
Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a combined behavioral and pharmacological intervention provided by a multidisciplinary team will further reduce LDL-C, smoking, BP and Hb-A1C in diabetic patients with A1c between 7% and 9% when compared to usual care.

Official Title
-----------------
Effectiveness of Different Strategies in Maintaining Target Goals of Cardiovascular Risk Factors in Patients Discharged From Cardiovascular Risk Reduction Clinic

Conditions
-----------------
Diabetes, Dyslipidemia, Hypertension, Coronary Atherosclerosis

Intervention / Treatment
-----------------
* Behavioral: Counseling
* Behavioral: Interactive Education
* Behavioral: Group Support
* Procedure: Pharmacologic case management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previous enrollment in Cardiovascular Risk Reduction Clinic (CRRC) Eligible for CRRC discharge: For DM patients: HbA1c < 7.0 %, BP < 130/85 mm Hg , and LDL < 100 mg/dl; For Non-DM patients: BP < 140/90 mm Hg, and LDL < 100 mg/dl; Able and willing to sign informed consent. Exclusion Criteria: Presence of conditions that might limit long-term compliance (eg, dementia, acute psychiatric decompensation within the previous 6 months, unstable psychiatric disorder); Metastatic disease or terminal illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group intervention<br>pharmacist-led group intervention in behavioral and pharmacologic therapy | Behavioral: Counseling<br> <br> Behavioral: Interactive Education<br> <br> Behavioral: Group Support<br> <br> Procedure: Pharmacologic case management<br>* Provided by clinical pharmacists<br>|
| Active Comparator: individual<br>pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction | Behavioral: Counseling<br> <br> Procedure: Pharmacologic case management<br>* Provided by clinical pharmacists<br>|
| No Intervention: usual care<br>usual care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of patients who had non-compliance to ADA target goals in smoking, LDL cholesterol, blood pressure or Hb A1c. |  | 12 months |
Usage of the Home Macular Perimeter (HMP)

Study Overview
=================
Brief Summary
-----------------
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.

Detailed Description
-----------------
The pilot study purpose is to demonstrate that the tutorial which is part of the device software, is giving sufficient training for the intended users.

Official Title
-----------------
Usage of the Home Macular Perimeter (HMP) in Intermediate Age Related Macular Degeneration Patients Pilot Study

Conditions
-----------------
Age Related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Capable and willing to sign a consent form and participate in the study Subjects diagnosed as intermediate AMD in at least one eye Age >50 years VA with habitual correction >20/60 in the study eye Ability to speak, read and understand instructions in Hebrew Familiar with computer usage Exclusion Criteria: Evidence of macular disease other than AMD or glaucoma in the study eye Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, CFP. Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye Participation in another study with the exclusion of AREDS study Patients diagnosed with geographic atrophy (GA)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Subjects diagnosed as intermediate AMD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects who manage to use the device as in a daily testing |  | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HMP, AMD, CNV, PHP, HPHP
Determinants of Obtaining Covid Vaccination Among Health Care Workers

Study Overview
=================
Brief Summary
-----------------
Despite the global preventive efforts (physical distancing, face, mask, travel constraints, and quarantine) to contain the infection, COVID-19 is continuing with its devastating consequences on health, life, and economics. The world's hopes are attached to a successful preventive measure that is the vaccination which has proved its capability to stop infections and save lives over the years. World Health Organization (WHO) declared vaccination hesitancy as one of the top 10 obstacles for global health. Multicentric study involved Arab countries measure hesitancy of HCWs toward vaccine, it reported the highest rates of hesitancy were among participants from the western regions of the Arab world (Egypt, Morocco, Tunisia, and Algeria). This study aims to evaluate the attitude and the determinants of this attitude of HCWs towards receiving or refusing to have their first dose of vaccination.

Official Title
-----------------
Determinants of Obtaining COVID-19 Vaccination Among Health Care Workers Accessible to Free COVID-19 Vaccination: a Cross Sectional Study

Conditions
-----------------
COVID-19 Vaccination

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All staff how are working in AUH and offered to receive the first dose of AstraZeneca & Sino pharm vaccine. Exclusion Criteria: Those who are not eligible to receive the vaccine Those who are not freely offered to receive the vaccine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of acceptance among HCWs who offered COVID-19 vaccine | to evaluate the rate of acceptance or refusal of receiving COVID-19 vaccines among health care workers | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Reasons for acceptance 2. Reasons for refusal 1. Reasons for acceptance 2. Reasons for refusal the response for COVID-19 vaccination acceptance or refusal | to understand the causes of vaccination acceptance or refusal among HCWs | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Vaccine, acceptance, attitude
Transverse vs Longitudinal Incision in Myomectomy

Study Overview
=================
Brief Summary
-----------------
The Aim of the study is to compare between transverse and longitudinal uterine incision in abdominal myomectomy regarding intraoperative blood loss.

Official Title
-----------------
Transverse Versus Longitudinal Uterine Incision in Abdominal Myomectomy

Conditions
-----------------
Myoma;Uterus

Intervention / Treatment
-----------------
* Procedure: Longitudinal uterine incision
* Procedure: Transverse uterine incision


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion criteria for myomectomy as; abnormal uterine, pressure related symptoms, infertility and recurrent pregnancy loss in patients between 18 and 45 years old Single myoma. Women with BMI between 18.5-29.9 kg/m2. Exclusion Criteria: Pregnancy. Patients with bleeding tendency Previous laparotomies. Patients with concomitant pelvic pathologies, such as ovarian cysts.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 1<br>26 subjects who are planned for transverse uterine incision | Procedure: Transverse uterine incision<br> <br> |
| Active Comparator: Group 2<br>26 subjects who are planned for longitudinal uterine incision | Procedure: Longitudinal uterine incision<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative blood loss |  | 1 year |
Study Evaluating LXR-623 in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Official Title
-----------------
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: LXR-623


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Healthy, men or women, aged 19-50 years Exlcusion: Use of any investigational or prescription drug within 30 days before study start Any clinically imprtant medical disease or abnormal laboratory test results

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: LXR-623|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and Tolerability |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Safety, Healthy, healthy subjects
Internal Iliac Artery Ligation and Abnormally Invasive Placenta

Study Overview
=================
Brief Summary
-----------------
This trial is set to detect the impact of bilateral internal iliac artery ligation on the amount of intra-operative blood loss during the hysterectomy procedure done for the management of abnormally invasive placenta

Conditions
-----------------
Placenta Percreta

Intervention / Treatment
-----------------
* Procedure: internal iliac artery ligation
* Procedure: Cesarean Hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: females with pre-operative diagnosis of abnormally invasive placenta Exclusion Criteria: refusal to get enrolled in the study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Internal Iliac artery ligation group<br>in this group the patients will undergo bilateral internal iliac artery ligation prior to the hysterectomy procedure | Procedure: internal iliac artery ligation<br> <br> Procedure: Cesarean Hysterectomy<br> <br> |
| Active Comparator: Hysterectomy only<br>in this group patients will undergo cesarean hysterectomy only | Procedure: Cesarean Hysterectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| amount of intra-operative hemorrhage |  | 2-3 hours |
Dataglove to Measure Joint Stiffness in Patients With Arthritis

Study Overview
=================
Brief Summary
-----------------
This study will investigate if an electronic dataglove can be used to measure joint stiffness in patients with Rheumatoid Arthritis.

Detailed Description
-----------------
We will use a dataglove to record joint movements in a small number of patients with rheumatoid arthritis. The aim of the study is to find out if changes in dynamic movements measured by the glove will correlate with symptoms of joint stiffness in the hands of patients with rheumatoid arthritis.

Official Title
-----------------
The Evaluation of a Dataglove to Measure Joint Stiffness in Patients With Arthritis

Conditions
-----------------
Arthritis, Rheumatoid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients aged 18 to 80 Diagnosis of Rheumatoid arthritis Patients who have significant pain and stiffness in their hands Correct hand size to achieve a good fit to the dataglove Able to follow instructions for use of dataglove/computer Exclusion Criteria: Severe pain in the right hand Severe swelling in the right hand (rated as such by the investigator) Severe permanent deformity or loss of function in the fingers of the right hand Broken or infected skin in the right hand Known to have been MRSA positive currently or in the past Unable to don and doff the disposable lining glove and the dataglove without significant discomfort Poor fit for the disposable lining glove or the dataglove History of latex allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arthritis patients<br>Patients with Rheumatoid Arthritis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between maximum velocity of movement and the patient reported severity of joint stiffness | A significant inverse correlation is expected to be found between the patient's assessment of the severity and/or duration of stiffness and the maximum velocity of movement at the main finger joints. | Maximum of 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients withdrawing from the study | We are expecting that no more than 30% of patients will withdraw from the study due to discomfort fitting or using the dataglove. | Over the period of testing of the dataglove - 7 day timeframe | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arthritis, Stiffness, Range of movement, Goniometry, Digital, Dataglove, Outcome
Development of a Novel Methodology Using BMVC Staining as an Assistance to Cancer Cytological Diagnosis

Study Overview
=================
Brief Summary
-----------------
3,6-bis(1-methyl-4-vinylpyridinium) carbazole diiodide (BMVC) is an inorganic chemical compound (Figure1). The uptake of BMVC in cancer cells and normal cells are different. Recently, a simple handheld device (Figure1) based on the fluorescence analysis of stained cells was established to instantly differentiate cancer cells from normal cells. The investigators want to quantitatively measure the fluorescence expression of BMVC in normal and cancer cells and explore the usefulness of this staining in head and neck lumps.

Conditions
-----------------
Neck Mass

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients (age range from 18 to 90 years old) with neck lumps, receiving sonographic examination and FNA cytologic study. Exclusion Criteria: No cytology data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neck masses<br>Neck mass received US and US-FNA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neck mass, ultrasound, FNA, BMVC